SCHEMBL3665141

SCHEMBL3665141

CCOC(=O)N1CCn2c(nc(-c3ccncn3)cc2=O)C(NCc2ccc(OC)cc2OC)C1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 13/20 0.45
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 1/20 0.39
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 4/20 0.39
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL914927 0.90 GSK3B (0.47) GSK3BALDH1A1SMN1; SMN2CYP1A2CYP3A4
SCHEMBL3662330 0.84 GSK3B (0.47) GSK3BCYP1A2CYP3A4CYP2D6
Hydrochloric Acid SCHEMBL3665578 0.83 GSK3B (0.47) GSK3BCYP1A2CYP3A4CYP2D6
SCHEMBL3664584 0.81 GSK3B (0.46) GSK3BCYP1A2CYP2D6
SCHEMBL15158304 0.80 MEN1 (0.41) GSK3BALDH1A1KDM4ESMN1; SMN2CYP2D6
SCHEMBL3665691 0.79 GSK3B (0.45) GSK3BCYP1A2CYP2D6TDP1
SCHEMBL3662447 0.79 GSK3B (0.45) GSK3BCYP1A2CYP2D6NOS1NOS2
SCHEMBL3662679 0.78 GSK3B (0.44) GSK3BALDH1A1SMN1; SMN2CYP1A2CYP2D6
SCHEMBL1832106 0.78 GSK3B (0.49) GSK3BCYP2D6
SCHEMBL916300 0.78 GSK3B (0.49) GSK3BCYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2238141-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA Sanofi-Aventis (FR) 2010-10-13 EP claimed
WO-2009095789-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA SANOFI-AVENTIS (FR) 2009-08-06 WO claimed
EP-2238141-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA Sanofi-Aventis (FR) 2010-10-13 EP disclosed
WO-2009095789-A1 SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES CAUSED BY ABNORMAL ACTIVITY OF GSK3-BETA SANOFI-AVENTIS (FR) 2009-08-06 WO disclosed